Inclusion Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Immunoglobulin G or immunoglobulin A (IgA) multiple myeloma
Low or intermediate risk disease based on the following criteria: Cytogenetics: no
translocations, 11q, or -13/13q- Beta-2 microglobulin less than 2.5 mg/L before the first
autologous peripheral blood stem cell transplantation (APBSCT) M-protein concentration in
harvested plasma greater than 50% of total immunoglobulin of corresponding isotype
(M-protein must be able to be purified by protein A- or anti-IgA-sepharose) Patients
achieving partial or complete response after the first APBSCT eligible --Prior/Concurrent
Therapy-- Biologic therapy: See Disease Characteristics No prior APBSCT with CD34 selected
stem cells Chemotherapy: Not specified Endocrine therapy: Steroids must be discontinued at
least 4 weeks prior to vaccination No concurrent steroids Radiotherapy: Not specified
Surgery: Not specified Other: Any prior therapy must be completed at least 8 weeks prior
to second APBSCT Recovered from the toxic effects of prior therapy No concurrent aspirin
or nonsteroidal antiinflammatory drugs --Patient Characteristics-- Age: 18 and over
Performance status: Karnofsky 70-100% Life expectancy: More than 8 weeks Hepatic:
Bilirubin less than 2.0 mg/dL and not rising for at least 2-4 weeks before transplantation
SGOT no greater than 4 times upper limit of normal and not rising for at least 2-4 weeks
before transplantation Renal: Creatinine less than 2 times normal and not rising for at
least 2-4 weeks before transplantation OR Creatinine clearance greater than 40 mL/min
Cardiovascular: LVEF greater than 50% by MUGA scan Pulmonary: DLCO greater than 50%
predicted Other: No other medical condition that would increase risk of transplantation
HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients must use
effective contraception